<DOC>
	<DOCNO>NCT01861912</DOCNO>
	<brief_summary>The purpose study determine whether compare arsenic trioxide TACE alone , arsenic trioxide TACE intravenous administration could prolong overall survival .</brief_summary>
	<brief_title>Arsenic Trioxide TACE Intravenous Administration Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Chlorotrianisene</mesh_term>
	<mesh_term>Ethiodized Oil</mesh_term>
	<criteria>Having sign informed consent ; Histological clinical diagnosis hepatocellular carcinoma（HCC） ; The target lesion least one diameter line available measurement , maximum diameter ≥5cm ≤10cm； Barcelona Clinic Liver Cancer stag B C ; ChildPugh liver function class : score≤7； Eastern Cooperative Oncology Group performance 0 1 ; At least 12 week life expectancy ; Never receive systemic treatment , oral molecularly target drug systemic chemotherapy ; Be able abide treatment followup plan； Adequate result laboratory test , include : 1 . Neutrophil count≥1.5×109/L , platelet count≥60×109 /L ; hemoglobin≥85g/L ; 2 . Total bilirubin≤51.3 μmol/L , albumin≥28 g/L , alanine aminotransferase aspartate aminotransferase≤5 time upper limit normal range ; 3 . Amylase lipase≤1.5 time upper limit normal range 4 . Serum creatinine≤20 g/L 5 . Prothrombin time international normalized ratio ≤1.7 ; prothrombin time≤4seconds control ; 6 . Left ventricular ejection fraction≥50 % accord twodimensional echocardiography ; Contraception : trail 12 week withdrawal , female childbearing age ( WOCBP ) , WOCBP whose male partner receive study drug male must use appropriate contraceptive avoid pregnancy ; Disease exclude : 1 . CT / MRI show diffuse lesion ; 2 . Extrahepatic metastasis ( metastasis lung include ) ; 3 . Invasion main portal vein / vena cava major vascular ; 4 . Previous shunt surgery ; 5 . PreviousTACE transarterial embolization HCC , unless untreated lesion ; 6 . Hepatic encephalopathy past present ; 7 . Current ascites require treatment ; Medical history concomitant disease : 1 . Previous current cancer HCC , unless cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis T1 ) . Cancer receive curative treatment 5 year ago exclude ; 2 . Disease history cardiovascular system follow : ( ) Uncontrolled hypertension； ( b ) Congestive heart failure New York Heart Association grade 3 4 ; ( c ) Active coronary artery disease within 12 month , unstable angina newly diagnose angina/myocardial infarction ; ( ) Arrhythmia require drug βblockers digoxin ; ( e ) Valvular heart disease ≥ CTCAE grade 2； c ) Corrected QT interval ( Fridericia ) &gt; 450 m confirm 2 ECGs row ) Thrombotic embolic event within 6 month , e ) Gastrointestinal bleeding within 6 month ; f ) Unstable / active stomach ulcer within 6 month , unless gastroscopy show fully recover ; g ) Variceal bleed within 6 month ; h ) Unhealed wound ulcer , fracture within 3 month ; ) Major surgery , open biopsy , severe trauma within 3 week ; j ) History organ transplant subject transplant wait list ; k ) Uncontrolled abnormal thyroid function ; l ) HIV infection ; ) Active untreated hepatitis B ; laboratory test unsuitable enrollment： 1 . Hyponatremia , serum sodium &lt; 130 mmol / L； 2 . Hypokalemia , serum potassium &lt; 3.5 mmol / L； Allergic reaction arsenic trioxide drug use trail ; Forbidden therapy and/or drug : 1 . Condensation treatment ( e.g. , warfarin heparin ) ; 2 . Chronic antiplatelet therapy ( Aspirin ≥ 300 mg / day ; clopidogrel ≥ 75 mg / day ) ; 3 . Radiotherapy within 4 week ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Carcinoma , Hepatocellular</keyword>
	<keyword>Arsenic trioxide</keyword>
</DOC>